Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002124687 | SCV002409607 | benign | not provided | 2022-07-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002500046 | SCV002809168 | likely benign | Focal segmental glomerulosclerosis 2 | 2022-03-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003015354 | SCV003733984 | uncertain significance | Inborn genetic diseases | 2021-07-09 | criteria provided, single submitter | clinical testing | The c.667A>G (p.I223V) alteration is located in exon 2 (coding exon 2) of the TRPC6 gene. This alteration results from a A to G substitution at nucleotide position 667, causing the isoleucine (I) at amino acid position 223 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV002124687 | SCV005334565 | uncertain significance | not provided | 2024-02-27 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |